Get the Stockscreener App
0.23
3.56%
-0.0085
After Hours:
.23
Marinus Pharmaceuticals Inc stock is traded at $0.23, with a volume of 1.13M.
It is down -3.56% in the last 24 hours and down -25.57% over the past month.
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.
See More
Previous Close:
$0.2385
Open:
$0.241
24h Volume:
1.13M
Relative Volume:
0.44
Market Cap:
$12.69M
Revenue:
$30.99M
Net Income/Loss:
$-141.41M
P/E Ratio:
-1.5333
EPS:
-0.15
Net Cash Flow:
$-118.12M
1W Performance:
-12.48%
1M Performance:
-25.57%
6M Performance:
-82.96%
1Y Performance:
-97.52%
1-Day Range:
$0.23
$0.2472
1-Week Range:
$0.23
$0.2583
52-Week Range:
$0.23
$11.26
Marinus Pharmaceuticals Inc Stock (MRNS) Company Profile
Name
Marinus Pharmaceuticals Inc
Sector
Industry
Phone
484-801-4670
Address
5 RADNOR CORPORATE CENTER SUITE 500, RADNOR, PA
Compare MRNS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNS
Marinus Pharmaceuticals Inc
|
0.23 | 12.69M | 30.99M | -141.41M | -118.12M | -2.63 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Marinus Pharmaceuticals Inc Stock (MRNS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-23-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Aug-14-24 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Apr-16-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-15-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-11-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-20-23 | Initiated | RBC Capital Mkts | Outperform |
| Sep-30-20 | Initiated | Truist | Buy |
| Jul-01-20 | Initiated | Cowen | Outperform |
| Jul-01-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-09-20 | Initiated | Craig Hallum | Buy |
| Dec-20-19 | Initiated | Oppenheimer | Outperform |
| Mar-05-19 | Resumed | Jefferies | Buy |
| Feb-27-19 | Downgrade | Mizuho | Buy → Neutral |
| Feb-06-19 | Initiated | Leerink Partners | Outperform |
| Jul-02-18 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-20-18 | Initiated | Mizuho | Buy |
| Feb-15-18 | Initiated | H.C. Wainwright | Buy |
| Dec-14-17 | Initiated | Laidlaw | Buy |
| Aug-10-16 | Reiterated | Jefferies | Buy |
| Jun-14-16 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-08-16 | Reiterated | Stifel | Buy |
| Dec-17-15 | Initiated | RBC Capital Mkts | Outperform |
| Nov-17-15 | Initiated | Jefferies | Buy |
| Oct-30-15 | Reiterated | Oppenheimer | Outperform |
| Aug-05-15 | Reiterated | Oppenheimer | Outperform |
View All
Marinus Pharmaceuticals Inc Stock (MRNS) Latest News
Marinus Pharma stock hits 52-week low at $0.23 - Investing.com India
Marinus Pharma stock hits 52-week low at $0.23 By Investing.com - Investing.com Australia
Layoff Tracker: Editas Will Cut 60% of Staff - BioSpace
Marinus Pharmaceuticals' SWOT analysis: epilepsy drug maker's stock faces pivotal moment - Investing.com
Marinus Pharma stock hits 52-week low at $0.26 amid steep decline - Investing.com
Marinus Pharma stock hits 52-week low at $0.26 amid steep decline By Investing.com - Investing.com South Africa
Marinus Pharmaceuticals faces Nasdaq delisting risk - Investing.com
Marinus Pharmaceuticals faces Nasdaq delisting risk By Investing.com - Investing.com Nigeria
Marinus Pharmaceuticals' SWOT analysis: stock faces challenges amid pipeline setbacks By Investing.com - Investing.com South Africa
Marinus Pharmaceuticals' SWOT analysis: stock faces challenges amid pipeline setbacks - Investing.com India
MRNS (Marinus Pharmaceuticals) Enterprise Value : $31.67 Mil (As of Dec. 02, 2024) - GuruFocus.com
MRNS (Marinus Pharmaceuticals) Revenue per Share : $0.55 (TTM As of Sep. 2024) - GuruFocus.com
Shareholders that lost money on Marinus Pharmaceuticals, Inc.(MR - GuruFocus.com
MRNS (Marinus Pharmaceuticals) Net Income : $-140.49 Mil (TTM As of Sep. 2024) - GuruFocus.com
Marinus Pharmaceuticals (LTS:0JYL) COGS-to-Revenue : 0.08 (As of Sep. 2024) - GuruFocus.com
Levi & Korsinsky Notifies Marinus Pharmaceuticals, Inc. Investor - GuruFocus.com
CDKL5 Deficiency Disorder Market Revenue to Expand Significantly by 2034, States DelveInsight Report | Marinus Pharma, Takeda, Zogenix, Inc., UCB, Ultragenyx Pharma - The Globe and Mail
CDKL5 Deficiency Disorder Market Revenue to Expand - openPR
Marinus Pharmaceuticals Reports Q3 2024 Financial Results and Strategic Developments - MSN
MRNS (Marinus Pharmaceuticals) Degree of Operating Leverage : 65.26 (As of Jun. 2024) - GuruFocus.com
Marinus Pharmaceuticals Third Quarter 2024 Earnings: Revenues Disappoint - Simply Wall St
US$1.86: That's What Analysts Think Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Is Worth After Its Latest Results - Yahoo Finance
Marinus Pharmaceuticals Lays Off 45% of Employees - BioSpace
Marinus Pharmaceuticals Faces Financial Turmoil Amidst Class Action Lawsuit - TipRanks
Marinus Pharmaceuticals Reports Q3 Growth in ZTALMY Revenue - TipRanks
Marinus Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Marinus Pharmaceuticals' SWOT analysis: navigating challenges in rare epilepsy stock - Investing.com India
Marinus Pharmaceuticals: Q3 Earnings Snapshot - Darien Times
Marinus Pharmaceuticals (MRNS) Reports Q3 Loss, Misses Revenue Estimates - MSN
Marinus Pharmaceuticals Inc Reports Q3 2024 Revenue of $8.54M, G - GuruFocus.com
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results - The Bakersfield Californian
Marinus Pharmaceuticals Faces Setback with Phase 3 TrustTSC Trial - MSN
Marinus Pharmaceuticals' SWOT analysis: rare epilepsy drug maker's stock faces pivotal moment - Investing.com Canada
Greenlane Holdings to Distribute CURB’s Innovative Inhalation Device: A Game-Changer? - BP Journal
Marinus Pharmaceuticals' SWOT analysis: rare epilepsy drug maker's stock faces pivotal moment By Investing.com - Investing.com South Africa
Marinus Pharmaceuticals Inc Stock (MRNS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Marinus Pharmaceuticals Inc Stock (MRNS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Pfanstiel Steven | CFO AND COO |
Aug 05 '24 |
Sale |
1.13 |
4,657 |
5,262 |
79,773 |
| Shafer Christina | CHIEF COMMERCIAL OFFICER |
Aug 05 '24 |
Sale |
1.14 |
3,820 |
4,355 |
67,406 |
| MANNING MARTHA E | SVP, GEN. COUNSEL & CORP. SEC. |
Aug 05 '24 |
Sale |
1.13 |
3,621 |
4,092 |
60,263 |
| Hulihan Joseph | CHIEF MEDICAL OFFICER |
Aug 05 '24 |
Sale |
1.13 |
4,828 |
5,456 |
72,725 |
| Braunstein Scott | CHAIRMAN AND CEO |
Aug 05 '24 |
Sale |
1.13 |
12,145 |
13,724 |
298,667 |
| Braunstein Scott | CHAIRMAN AND CEO |
Mar 27 '24 |
Option Exercise |
4.28 |
50,000 |
214,000 |
273,512 |
| Shafer Christina | CHIEF COMMERCIAL OFFICER |
Feb 20 '24 |
Sale |
9.56 |
2,153 |
20,583 |
60,308 |
| MANNING MARTHA E | SVP, GEN. COUNSEL & CORP. SEC. |
Feb 20 '24 |
Sale |
9.57 |
1,894 |
18,126 |
52,966 |
| Hulihan Joseph | CHIEF MEDICAL OFFICER |
Feb 16 '24 |
Sale |
9.98 |
2,814 |
28,084 |
66,635 |
| Pfanstiel Steven | CFO AND COO |
Feb 16 '24 |
Sale |
9.97 |
3,092 |
30,827 |
71,697 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):